--> +4.70% in pre mkt - low volume
Cynosure beats by $0.03, beats on revs (50.15)
- Reports Q4 (Dec) earnings of $0.44 per share, $0.03 better than the Capital IQ Consensus of $0.41; revenues rose 19.2% year/year to $122.1 mln vs the $119.97 mln Capital IQ Consensus.
- "Demand for aesthetic procedures in North America was our largest growth driver over the course of 2016, led by the full launch of our SculpSure platform in the first quarter," Davin said. "Our international business gained momentum in the second half of 2016, reflecting our focus on securing additional regulatory clearances such as the third quarter 2016 marketing approval of SculpSure in Korea and the China Food and Drug Administration's clearance of the Icon Aesthetic System in November."
- "We begin 2017 with a high degree of optimism, confident that we have the right product portfolio, technology and distribution to capitalize on the trends that will shape the aesthetic market in the quarters and years ahead," Davin said. "Our strategy positions us to generate sustained growth from diverse revenue sources, drive long-term profitability and deepen our competitive advantage."